Synergy Pharmaceuticals LLC

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with immediate effect. Bernard F. Denoyer (age: 74) Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA approval and his retirement in June 2017. From January 2004 until January 2013. Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. While with SGYP and CLSP he supported over $500M of public and PIPE financings with related due diligence, SEC registrations and market listings. From October 2000 to December 2003, Mr. Denoyer was an independent consultant, providing interim CFO and other services to emerging businesses, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., an information technology research company. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honors from Columbia Business School in 1972, and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He served in U.S. Army in Vietnam from 1969 to 1971 and has been an adjunct accounting professor at Fairfield University and the Marymount College. He is currently serving on the Board of Trustees for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc. Mr Denoyer will assume the role chair the Nomination Committee of the Board from Mr Gabriele Cerrone (who will continue to serve as a member of the Nomination Committee). With immediate effect Willy Simon will assume the role of senior non-executive and will continue to chair the Remuneration Committee of the Board. Gabriele Cerrone, Chairman of OKYO, said, "We are delighted that Bernard has joined the Board of OKYO. His expertise will be of great value to us at a very important time for the group." There are no other disclosures to make pursuant to Listing Rule 9.6.13, in respect of Mr Denoyer's appointment. The person who approved the content of this announcement for purposes of UK MAR was Dr Gary Jacob, Chief Executive Officer. About OKYO OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Enquiries: OKYO Pharma Limited Gabriele Cerrone +44 (0)20 7382 8300 Optiva Securities Limited Robert Emmet +44 (0)20 3981 4173 For further information, please visit the Company's website at

SAN FRANCISCO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) of the April 10, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Synergy securities between September 5, 2017 and November 14, 2017 and suffered losses, contact Hagens Berman Sobol Shapiro LLP.  For more information, visit: https://www.hbsslaw.com/cases/SGYP or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing SGYP@hbsslaw.com . The Complaint charges Defendants with making false or misleading statements about the terms of a $300 million senior secured loan to Synergy from CRG Partners III L.P.  More specifically, the Complaint charges Defendants falsely described this financing as non-dilutive to shareholders on September 5, 2017. When Synergy filed the CRG loan agreement with the SEC on November 9, 2017, it revealed that the financing would likely be dilutive to shareholders.  This news drove the price of Synergy shares down $0.25, or about 8.4%, to close at $2.72 on November 10, 2017. On November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares.  This news drove the price of Synergy shares down $0.14, or about 6.9% to close at $1.89 on November 15, 2017. “We’re focused on the defendants’ statements about the financing’s impact on equity investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email SGYP@hbsslaw.com . About Hagens Berman Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes can be found at www.hbsslaw.com .  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw . Contact: Reed Kathrein, 510-725-3000

DelveInsight's, Constipation Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Constipation. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Constipation. This report provides information on the therapeutic development for Constipation, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report. The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. Forest Labs and Ironwood Pharmaceuticals;AstraZeneca;Shionogi;Synergy Pharmaceuticals;Enterin Inc.;Kyowa Kirin Pharmaceutical Development Ltd;RaQualia Pharma Inc;AstraZeneca;KGK Synergize Inc.;Sucampo Pharmaceuticals Inc.;Ardelyx;Mundipharma China Pharmaceutical Co. Ltd;Purdue Pharma LP;Aboca Spa Societa' Agricola;Merck Sharp Dohme Corp.;Admescope Ltd;Yakult Constipation Pipeline Drugs Constipation Pipeline Assessment Constipation Pipeline Analysis Constipation Drugs under Development Constipation Discovery drugs Constipation Preclinical drugs Constipation Phase I drugs Constipation Phase II drugs Constipation Phase III Pipeline Drugs Assessment Constipation Preregistration drugs Constipation Molecules in pipeline